Hill-Rom Holdings, Inc. (HRC) CEO John J. Greisch Sells 125,241 Shares

Hill-Rom Holdings, Inc. (NYSE:HRC) CEO John J. Greisch sold 125,241 shares of the company’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $82.59, for a total value of $10,343,654.19. Following the completion of the transaction, the chief executive officer now owns 280,851 shares of the company’s stock, valued at approximately $23,195,484.09. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Hill-Rom Holdings, Inc. (HRC) traded down $1.31 during trading hours on Friday, hitting $81.84. The company’s stock had a trading volume of 429,100 shares, compared to its average volume of 500,960. Hill-Rom Holdings, Inc. has a 1 year low of $54.59 and a 1 year high of $85.25. The stock has a market cap of $5,484.86, a PE ratio of 21.59, a P/E/G ratio of 1.77 and a beta of 1.19. The company has a current ratio of 1.77, a quick ratio of 1.34 and a debt-to-equity ratio of 1.55.

Hill-Rom (NYSE:HRC) last released its quarterly earnings results on Friday, November 3rd. The medical technology company reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.27 by $0.05. Hill-Rom had a return on equity of 20.27% and a net margin of 4.87%. The firm had revenue of $738.30 million for the quarter, compared to analysts’ expectations of $731.10 million. During the same quarter last year, the firm posted $1.18 EPS. The company’s revenue was up 4.6% compared to the same quarter last year. equities analysts expect that Hill-Rom Holdings, Inc. will post 4.26 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 15th will be issued a dividend of $0.18 per share. The ex-dividend date is Thursday, December 14th. This represents a $0.72 dividend on an annualized basis and a dividend yield of 0.88%. Hill-Rom’s dividend payout ratio is 36.18%.

Several hedge funds and other institutional investors have recently made changes to their positions in HRC. Seven Eight Capital LP bought a new position in Hill-Rom during the 2nd quarter worth approximately $127,000. Acrospire Investment Management LLC grew its position in Hill-Rom by 43.4% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,983 shares of the medical technology company’s stock worth $158,000 after acquiring an additional 600 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Hill-Rom by 10.2% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,201 shares of the medical technology company’s stock worth $175,000 after acquiring an additional 204 shares during the last quarter. Citigroup Inc. grew its position in Hill-Rom by 21.1% during the 2nd quarter. Citigroup Inc. now owns 2,483 shares of the medical technology company’s stock worth $198,000 after acquiring an additional 433 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale grew its position in Hill-Rom by 101.0% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 2,720 shares of the medical technology company’s stock worth $204,000 after acquiring an additional 1,367 shares during the last quarter. 82.35% of the stock is currently owned by institutional investors.

A number of brokerages have issued reports on HRC. Zacks Investment Research upgraded Hill-Rom from a “sell” rating to a “hold” rating in a research note on Tuesday, September 26th. Stifel Nicolaus reiterated a “buy” rating and set a $92.00 price target on shares of Hill-Rom in a research note on Wednesday, November 29th. ValuEngine downgraded Hill-Rom from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. KeyCorp reiterated a “buy” rating and set a $82.00 price target on shares of Hill-Rom in a research note on Tuesday, October 17th. Finally, Bank of America reiterated a “hold” rating on shares of Hill-Rom in a research note on Wednesday, November 22nd. Five equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $89.57.

ILLEGAL ACTIVITY NOTICE: This article was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://ledgergazette.com/2017/12/15/hill-rom-holdings-inc-hrc-ceo-john-j-greisch-sells-125241-shares.html.

Hill-Rom Company Profile

Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.

Insider Buying and Selling by Quarter for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply